Dr. Cho on the Knowledge Deficit in Multiple Myeloma

Hearn Jay Cho, MD, PhD
Published: Saturday, Dec 15, 2018



Hearn Jay Cho, MD, PhD, associate professor of medicine, Hematology/Oncology, Icahn School of Medicine, Mount Sinai Hospital, discusses the knowledge deficit in multiple myeloma.

The biggest deficit is in our understanding of a drug’s mechanism of action, explains Cho. For example, elotuzumab (Empliciti) and daratumumab (Darzalex) were initially thought to be targeting antibodies. It is now known that these agents have activities beyond their ability to code the tumor cell.

These agents have a big impact on immunity, particularly antitumor immunity; the molecules that these agents target—CD38 and SLAMF7—have immunologic functions. However, their precise mechanism of action still needs to be understood in order to know what the contribution of the targeting antibody function is. Understanding the mechanisms of these agents can be used to inform how to logically combine them. That's the knowledge deficit that needs to be filled right now, states Cho.
SELECTED
LANGUAGE


Hearn Jay Cho, MD, PhD, associate professor of medicine, Hematology/Oncology, Icahn School of Medicine, Mount Sinai Hospital, discusses the knowledge deficit in multiple myeloma.

The biggest deficit is in our understanding of a drug’s mechanism of action, explains Cho. For example, elotuzumab (Empliciti) and daratumumab (Darzalex) were initially thought to be targeting antibodies. It is now known that these agents have activities beyond their ability to code the tumor cell.

These agents have a big impact on immunity, particularly antitumor immunity; the molecules that these agents target—CD38 and SLAMF7—have immunologic functions. However, their precise mechanism of action still needs to be understood in order to know what the contribution of the targeting antibody function is. Understanding the mechanisms of these agents can be used to inform how to logically combine them. That's the knowledge deficit that needs to be filled right now, states Cho.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How to Use Liquid Biopsies Throughout the Lung Cancer Treatment Continuum OnlineJan 31, 20191.5
Community Practice Connections™: Current Status and the Future Potential of CAR T-Cell Therapy for Lymphoid Malignancies: The Experts Weigh-In on Recent Data and Clinical ExperienceJan 31, 20192.0
Publication Bottom Border
Border Publication
x